ABSTRACT
Background While the US Food and Drug Administration (FDA) has cleared smart watch software for detecting atrial fibrillation (AF), there is lack of guidance on management by physicians.
Methods We conducted a case-based survey of physicians in primary care, emergency medicine, and cardiology at Yale and University of California San Francisco from September to December 2021. Cases described asymptomatic patients receiving Apple Watch AF alerts; cases varied in sex, race, medical (diabetes and hypertension) history, and notification frequency. Physicians were asked to select from among prespecified diagnostic testing, referral, and treatment options.
Results We emailed 636 physicians, of whom 95 (14.9%) filled out the survey, including 39 primary care, 25 emergency medicine, and 31 cardiology physicians. Among a total of 192 cases (16 unique scenarios), physicians selected at least one diagnostic test in 191 (99.5%) cases and medications in 48 (25.0%). Rates of patient referral (14%, 30%, and 16%, respectively; P=.048), rhythm monitoring (84%, 46%, and 94%, respectively; P<.001), measurement of BNP (8%, 20%, and 2%; P=.003), and use of antiarrhythmics (16%, 4%, and 23%; P=.023) varied among primary care, emergency medicine, and cardiology, respectively. Management was largely consistent across case characteristics (race, sex, medical history, and alert frequency).
Conclusion In hypothetical cases of patients presenting without clinical symptoms, physicians opted for further diagnostic testing and often to medical intervention based on Apple Watch irregular rhythm notifications. There was also considerable variation across physician specialties, suggesting a need for uniform clinical practice guidelines.
Competing Interest Statement
PD reports Roivant Sciences stock options. SD reports research funding from the Department of Veterans Affairs, from the Medical Device Innovation Consortium (MDIC) as part of the National Evaluation System for health Technology Coordinating Center (NESTcc), Greenwall Foundation, Arnold Ventures, and National Institute for Health Care Management. ES receives grant funding from the Centers for Disease Control and Prevention (20042801-Sub01), National Institute on Minority Health and Health Disparities (U54MD010711-01), the U.S. Food and Drug Administration to support projects within the Yale-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI, U01FD005938), the National Institute of Biomedical Imaging and Bioengineering (R01 EB028106-01), and from the National Heart, Lung, and Blood Institute (R01HL151240). AB was employed by Apple Inc. 2018-2019 and held stock in Apple Inc. 2019-2021. JR currently receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology (NEST), from the Food and Drug Administration for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), from the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) (R01HS025164, R01HL144644), and from Arnold Ventures; in addition, JR is an expert witness at the request of Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. In addition to funding listed above, RK also receives research support, through Yale, from Bristol-Myers Squibb. He is a coinventor of U.S. Pending Patent Application No. 63/177,117, "Methods for neighborhood phenomapping for clinical trials", and U.S. Provisional Patent Application No. 63/346,610, "Articles and methods for format independent detection of hidden cardiovascular disease from printed electrocardiographic images using deep learning.” He is also a founder of Evidence2Health, a precision health platform to improve evidence-based cardiovascular care.
Funding Statement
The study was funded by the National Heart, Lung and Blood Institute (under award K23HL153775 to RK and T35HL007649 to PD), and the Doris Duke Charitable Foundation (under award, 2022060 to RK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRBs of Yale and UCSF waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Presentations: Poster at the 2022 American Heart Association Quality of Care and Outcomes Research (AHA QCOR) Scientific Session (Abstract 43).
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
